2023. PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. Biomedical Research and Therapy. 10, 12 (Dec. 2023), 6090–6102. DOI:https://doi.org/10.15419/bmrat.v10i12.851.